Pancreatic Cancer’s Hidden Gene Threat

A hand pointing at a brain scan with highlighted areas

A hidden “master gene” called KLF5 silently reprograms pancreatic cancer cells to spread like wildfire, bypassing the usual genetic mutations doctors have chased for decades.

Story Snapshot

Johns Hopkins researchers pinpoint KLF5 as the epigenetic driver fueling pancreatic cancer metastasis in 77% of studied cases.
Elevated KLF5 alters DNA packaging, activating invasion genes like NCAPD2 and MTHFD1 without changing DNA sequences.
Partial inhibition of KLF5 could stop tumor spread, offering hope for a cancer that kills 90% of patients via metastasis.
Study used cells from 13 patients, confirming higher KLF5 in metastatic sites versus primary tumors.
Shifts treatment focus from mutations like KRAS to under-appreciated epigenetics, with inhibitors already in development.

KLF5 Emerges as Metastasis Master Regulator

Johns Hopkins Medicine scientists identified KLF5, or Krüppel-like factor 5, as the key gene driving pancreatic ductal adenocarcinoma (PDAC) metastasis. KLF5 elevates in metastatic lesions from 10 of 13 patients, altering DNA packaging to boost tumor invasion. This epigenetic mechanism regulates genes NCAPD2 and MTHFD1, which control cell movement and treatment resistance. Lab-grown patient cells and mouse models validated these findings, revealing KLF5’s role in aggressive spread.

Epigenetics Trumps Mutations in Cancer Spread

PDAC starts with mutations in KRAS (95% of cases), CDKN2A, TP53, and SMAD4 in precursor PanIN lesions, progressing to invasive tumors. Mutations alone fail to explain metastasis, which causes 90% of deaths despite a 5-year survival under 10%. Andrew Feinberg’s 2017 work first tied epigenetic changes to spread. Recent studies confirm KLF5 as the “master regulator,” repackaging DNA to amplify invasion pathways without new mutations. This challenges mutation-centric views.

Kenna Sherman, first author and Johns Hopkins graduate student, stated KLF5 impacts genes controlling invasion and therapy resistance. Feinberg emphasized epigenetic alterations as under-appreciated, noting partial KLF5 shutdown might suffice to halt progression. Subtle switches often prove more potent than brute-force changes, especially in resilient cancers like PDAC.

Research Team and Collaborative Breakthrough

Andrew Feinberg, Bloomberg Distinguished Professor across Johns Hopkins medicine, engineering, and public health, leads the effort. He pioneered the 2017 epigenetics link. Kenna Sherman conducted core experiments. Contributors include Masahiro Maeda and Weiqiang Zhou at Johns Hopkins, Xingbo Shang and Andre Levchenko at Yale, and Jimin Min and Anirban Maitra at NYU Langone. Johns Hopkins drove lab work, with Yale and NYU adding modeling and pathology expertise. NIH and university grants fund the push for epigenetic therapies.

Preclinical Promise and Therapeutic Horizon

The study, published around 2025-2026, used patient-derived cells and DNA packaging assays to confirm KLF5’s dominance. Anti-KLF5 compounds exist in development, targeting 77% of metastatic cases with elevated levels. No human trials launch yet, but preclinical mouse data shows slowed spread. This builds on KRAS as initiator, positioning KLF5 as the metastatic amplifier. Uncertainties linger on clinical timelines and human efficacy, demanding rigorous validation.

Short-term, KLF5 inhibitors could curb lab metastasis. Long-term, epigenetics promises a PDAC survival boost, affecting 50,000 annual U.S. cases. New drugs might slash billions in late-stage costs, easing family burdens and spurring research funding. Oncology pivots toward non-mutational drivers, complementing targets like MICAL2 and DOCK8.